A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in the monkey

Brain Research

Volumn 766, Issue 1-2, 1997, Pages 107-112

  Bezard, Erwan ^a   Imbert, Christelle ^a   Deloire, Xavier ^a   Bioulac, Bernard ^a   Gross, Christian E ^a  

^a CNRS   (France)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Chronic model; Monkey; Parkinson's disease; Slow evolution of disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INTOXICATION; MONKEY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SCORING SYSTEM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CELL COUNT; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE AGENTS; LEVODOPA; MACACA FASCICULARIS; MOVEMENT; NEURONS; PARKINSON DISEASE, SECONDARY; TYROSINE 3-MONOOXYGENASE;

EID: 0030984413     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00531-3     Document Type: Article

References (45)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet. 337:1991;1321-1323.
2. Askari S., Mikhail E.W., Smith W.K., Woodward D.J., German D.C. Midbrain dopamine neurons in man: effects of Parkinson's disease on the regional distribution of cells. Soc. Neurosci. Abstr. 12:1986;83.
3. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppamn J.L., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of MPTP. Life Sci. 39:1986;7-16.
4. Benazzouz A., Boraud T., Stutzmann J.M., Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a preliminary study. Eur. J. Pharmacol. 284:1995;299-307.
5. Benazzouz A., Gross C., Bioulac B. MPTP-induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp. Brain Res. 90:1992;116-120.
6. E. Bezard, T. Boraud, B. Bioulac, C. Gross, Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism, Neuroscience (1997) in press.
7. Bezard E., Boraud T., Bioulac B., Gross C.E. Presymptomatic revelation of experimental parkinsonism. NeuroReport. 8:1997;435-438.
8. Boireau A., Dubédat P., Bordier F., Peny C., Miquet J.M., Durand G., Meunier M., Doble A. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. NeuroReport. 5:1994;2657-2660.
9. +-induced increase in striatal extracellular dopamine in rats in vivo. NeuroReport. 5:1994;2157-2160.
10. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.J., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
11. Chiueh C.C., Markey S.D., Burns R.S., Johannessen J.N., Jacobowitz D.M., Kopin I.J. Neurochemical and behavioral effects of MPTP in rat, guinea pig and monkey. Psychopharmacol. Bull. 20:1984;548-553.
12. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:1979;249-254.
13. Doudet D., Gross C., Lebrun-Grandie P., Bioulac B. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study. Brain Res. 335:1985;194-199.
14. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
15. Eidelberg E., Brooks B.A., Morgan W.W., Alden J.G., Kokemoor R.H. Variability and functional recovery in the MPTP model of parkinsonism in monkeys. Neuroscience. 18:1986;817-822.
16. Gerlach M., Riederer P., Przuntek H., Youdim M.B.H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208:1991;273-286.
17. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Med. 2:1996;1017-1021.
18. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48:1938;387-476.
19. Hirsch E.C. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol. Neurobiol. 9:1994;135-142.
20. Hoehn H.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
21. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
22. Javoy-Agid F., Taquet H., Ploska A., Cherif-Zahar C., Ruberg M., Agid Y. Distribution of catecholamines in the ventral mesencephalon of human brain, with special reference to Parkinson's disease. J. Neurochem. 36:1981;2101-2105.
23. Kupsch A., Gerlach M., Pupeter S.C., Sautter J., Dirr A., Arnold G., Opitz W., Przuntek H., Riederer P., Oertel W.H. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral but not at the striatal level in mice. NeuroReport. 6:1995;621-625.
24. Kurlan R., Kim M.H., Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Movement Disord. 6:1991;111-118.
25. Kurlan R., Kim M.H., Gash D.M. The time-course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of MPTP to monkeys. Ann. Neurol. 26:1991;677-679.
26. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I. Chronic parkinsonism in human due to a product of meperidine analog synthesis. Science. 219:1983;979-980.
27. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
28. Langston J.W., Widner H., Goetz C.G., Brooks D., Fahn S., Freeman T., Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov. Disord. 7:1992;2-13.
29. Paré D., Dossi R.C., Steriade M. Neuronal basis of the parkinsonian resting tremor: a hypothesis and its implication for treatment. Neuroscience. 35:1990;217-226.
30. Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.C., Laduron P., Stutzmann J.M. Neuroprotective action of riluzole in rodent models of global and focal cerebral ischemia. Neurosci. Lett. 140:1992;251-254.
31. Rose S., Nomoto M., Jackson E.A., Gibb W.R.G., Jaehnig P., Jenner P., Marsden C.D. Age-related effects of MPTP treatment of common marmosets. Eur. J. Pharmacol. 230:1993;177-185.
32. Rose S., Nomoto M., Kelly E., Kilpatrick G., Jenner P., Marsden C.D. Increased dopamine turn-over may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci. Lett. 101:1989;305-310.
33. Scherman D., Desnos C., Darchen F., Pollack P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26:1989;551-557.
34. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys Brain Res. 519:1990;122-128.
35. Schneider J.S., Lidsky T.I., Hawks T., Mazziotta J.C., Hoffman J.M. Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Brain Res. 672:1995;112-127.
36. Schneider J.S., Yuwiler A., Markham C.H. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411:1987;144-150.
37. Schultz W., Studer A., Jonsson G., Sundstrüm E., Mefford I. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Neurosci. Lett. 59:1985;225-232.
38. Stern Y. MPTP-induced parkinsonism. Prog. Neurobiol. 34:1990;107-114.
39. J.R. Taylor, J.D. Elsworth, R.H. Roth, J.R. Sladek, D.E. Redmond, Behavioral effects of MPTP administration in the Vervet monkey, a primate model of Parkinson's disease, in: M.L. Woodruff, A. Nonneman (Eds.), Toxin-induced Models of Neurological Disorders, Plenum Press, New York, 1994, pp. 139-151.
40. Tetrud J.W., Langston J.W. Tremor in MPTP-induced parkinsonism. Neurology. 42:1992;407-410.
41. Tomac A., Lindqvist E., Lin L.F.H., Ögren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-341.
42. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
43. Ueki A., Chong P.N., Albanese A., Rose S., Chivers J.K., Jenner P., Marsden C.D. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology. 28:1989;1089-1097.
44. Uhl G.R., Hedreen J.C., Price D.L. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 35:1985;1215-1218.
45. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G.U. MK-801 prevents MPTP-induced parkinsonism in primates. J. Neurochem. 2:1992;733-739.